Origins of the Fentynal Crisis - Part 1

Fentanyl was synthesized in 1960 by the Belgian pharmacologist Paul Janssen, whose team was systematically modifying the structure of meperidine (Demerol) to explore new analgesics. The logic was structural chemistry: both meperidine and morphine share a piperidine ring, which Janssen believed was responsible for their analgesic properties. By making the molecule more fat-soluble, his team produced compounds that penetrated the central nervous system faster and with greater potency. The resulting fentanyl family — including sufentanil, carfentanil, and alfentanil, developed through the 1970s — ranged from fentanyl itself to carfentanil, a veterinary immobilizing agent with a potency ratio over 16,000 times that of meperidine. Hektoen International

The medical rationale for such potency was actually about control, not intensity. In surgical anesthesia, a drug that works quickly and clears quickly allows precise management — patients can be brought to the required depth and returned to consciousness in a predictable window. Smaller doses meant less total drug in the body. The FDA approved fentanyl (marketed as Sublimaze) for intravenous use in 1968, and its adoption in surgical settings was rapid. At this stage it existed almost exclusively in hospitals under direct supervision; diversion was minimal. Esy

Interestingly, fentanyl had an easier path in Europe than in the US. A prominent American anesthesiologist, Dr. Robert Dripps, opposed its approval precisely because of its strength and potential for harm. A compromise was eventually reached: the FDA allowed it only in combination with droperidol in a fixed 50:1 ratio, marketed as Innovar. Georgia Addiction Treatment Center

The Critical Expansion: Out of the OR and Into the Home

In 1991, the FDA approved Duragesic, the first transdermal fentanyl patch — a pivotal moment because fentanyl could now be used outside hospital settings, prescribed for chronic pain and administered at home. In 1998, Actiq, an oral fentanyl lozenge, received approval for breakthrough cancer pain. The drug was moving from surgical suites to medicine cabinets. Esy

This was the crack in the wall. The patch was designed to release the drug slowly over 72 hours for cancer and end-stage chronic pain patients. But it created a new, exploitable form: a reservoir of fentanyl sitting in a household, accessible to diversion, misuse, and abuse. Patches could be chewed, heated, or extracted. The ease and effectiveness of these user-friendly delivery methods led to abuse. Pacific Northwest National Laboratory

Was It Foreseen? A Pattern Repeated

Yes, the warnings were there — and not only ignored, but actively suppressed. The broader opioid story is instructive.

By the late 1990s, a campaign funded and orchestrated by the opioid industry had elevated pain to "the fifth vital sign" and laid the groundwork for the blockbuster success of OxyContin, launched in 1996. As marketing intensified and prescribing expanded, so did diversion and addiction. Critics who raised concerns about addiction risk had their objections turned against them — a one-paragraph 1980 letter to the New England Journal of Medicine describing rare addiction in hospitalized patients was cited over 600 times, almost always without that crucial qualifier. Hopkins Bloomberg Public Health Magazine

There was also a specific, highly visible early warning about illicit fentanyl analogs. California saw deaths from "China White" — an illicit fentanyl analog — in the 1980s. These were underground chemists producing designer analogues specifically to stay one step ahead of drug scheduling laws. The DEA and public health community documented these incidents. They remained, as it turned out, a preview rather than an isolated anomaly. Esy

The Three-Wave Collapse

The opioid crisis unfolded in three distinct waves. The 1990s brought growth in overdose deaths from prescription opioids as physicians increasingly prescribed them for chronic conditions. A brief second wave in the early 2010s was driven by illegal heroin. Then synthetic opioids — fentanyl in particular — began driving a dramatic spike in deaths from around 2013 onward. Council on Foreign Relations

The transition between waves was not accidental. In 2010, Purdue reformulated OxyContin to make it harder to crush and abuse. This public health intervention had an unintended consequence: demand displacement. Users dependent on prescription opioids needed alternatives. Regulatory tightening created scarcity on the street, which accelerated the switch to heroin — and then, as heroin supply tightened, to fentanyl. Esy

The economics of fentanyl made it irresistible to traffickers. A kilogram of heroin could be purchased for approximately $6,000 and sold for around $80,000. For the same purchase price, a kilogram of illicitly imported fentanyl could be sold for approximately $1.6 million, then cut into heroin and other drugs to expand their volume. Pacific Northwest National Laboratory

The Supply Chain: China, Mexico, and the Iron Law of Prohibition

Around 2013–2014, fentanyl began emerging in the illicit US market on any large scale, and initially all of it came out of China. Chinese chemical manufacturers were exploiting loose regulatory enforcement to synthesize fentanyl and ship it directly to US consumers, often through ordinary postal services. Brookings

This followed what some researchers call the "Iron Law of Prohibition": when authorities attempt to suppress a drug supply, traffickers are pushed toward ever more compact and potent substitutes. When China moved to schedule fentanyl in 2019, several local drug laboratories emerged in Mexico and elsewhere in North America. International Journal of Mental Health Systems

By 2024, Mexico had become the most significant source of illicit fentanyl affecting the United States, while Chinese companies remained the largest source of precursor chemicals. Over 3,100 chemicals can potentially be used to manufacture fentanyl and its analogues, many of them common in academic and pharmaceutical settings, making global regulation extremely difficult. Congress.gov

As of April 2026, the International Narcotics Control Board reported the existence of 183 fentanyl-related substances with no known legitimate medical use, and the UN estimates that laboratories could potentially synthesize thousands more. Congress.gov

The honest summary is this: fentanyl's journey from surgical tool to street drug was not a failure of chemistry or pharmacology — it was a failure of regulatory will, commercial incentive, and institutional memory. Every step had a precedent. Heroin itself was introduced in 1898 as a supposedly non-addictive alternative to morphine. OxyContin was marketed as a safer opioid in 1996. The specific toxicity hazard of potent synthetic opioids was documented in the 1980s California deaths. What was missing was not foresight, but the political and economic infrastructure to act on it.

AI research article